EGFR and cancer: When inserting the adapter A2 between the RIP saporin and the targeting moiety EGF (Saporin-A2-EGF), an improved anti-cancer effect in mice with EGFR-positive tumors and simultaneously lesser side effects were observed in comparison to Saporin-EGF [22].